Using Dose Titration to Resolve Nausea on Zepbound (tirzepatide)

What does the label actually tell you to do?

The labeled schedule is built to reduce gastrointestinal adverse reactions, and the label says this escalation applies to all Zepbound indications [1]. It starts at 2.5 mg injected subcutaneously once weekly for 4 weeks, and the label states that the 2.5 mg dose is for treatment initiation and is not approved as a maintenance dose [1]. After 4 weeks the dose goes to 5 mg, then up in 2.5 mg increments, with each increase made after at least 4 weeks on the current dose [1].

The recommended maintenance doses are 5, 10 or 15 mg once weekly for weight reduction and long-term weight maintenance, and 10 or 15 mg once weekly for obstructive sleep apnea; the maximum is 15 mg once weekly [1]. The label says to consider treatment response and tolerability when selecting the maintenance dose [1].

What does the label say about timing?

The label gives tirzepatide a half-life of about 5 days, a median time to peak of 24 hours, and steady state after 4 weeks of once-weekly dosing [1]. It also describes delayed gastric emptying as an effect of the drug, with the delay largest after the first dose and diminishing over time [1].

How common is nausea at each dose?

In the pooled weight-management trials (SURMOUNT-1 and SURMOUNT-2, adults with obesity or overweight, with or without type 2 diabetes, up to 72 weeks), nausea was reported by 8% of placebo patients and by 25% on 5 mg, 29% on 10 mg and 28% on 15 mg [1]. Over the same trials, diarrhea was 8% on placebo versus 19%, 21% and 23% on 5, 10 and 15 mg; vomiting was 2% versus 8%, 11% and 13%; and constipation was 5% versus 17%, 14% and 11% [1].

Any gastrointestinal adverse reaction was reported by 56% of patients on every Zepbound dose, versus 30% on placebo, and treatment was discontinued for a gastrointestinal reason by 1.9% (5 mg), 3.3% (10 mg) and 4.3% (15 mg), versus 0.5% on placebo [1]. Severe gastrointestinal adverse reactions were reported by 1.7%, 2.5% and 3.1% across the three doses, versus 1% on placebo [1].

The label notes that adverse reaction rates from clinical trials cannot be directly compared between different drugs, so these figures describe Zepbound only [1].

Can you stay on a dose longer than 4 weeks?

The label's wording is "after at least 4 weeks on the current dose," so four weeks is a floor rather than a ceiling [1]. SURMOUNT-1 included a 20-week dose-escalation period [2]. Neither the label nor the SURMOUNT-1 report states whether holding a dose longer than the labeled minimum reduces nausea.

What if nausea follows a dose increase: can the dose go back down?

The label's explicit step-down instruction concerns maintenance doses: if patients do not tolerate a maintenance dosage, consider a lower maintenance dosage [1]. It gives no more specific instruction about moving back down during escalation.

The weight results at lower doses are substantial. In SURMOUNT-1, 2,539 adults with obesity, or with overweight plus a weight-related complication, and without diabetes had a mean weight change at week 72 of -15.0% on 5 mg, -19.5% on 10 mg and -20.9% on 15 mg, versus -3.1% on placebo [2].

What about missed doses and changing the injection day?

If a dose is missed, the label says to give it as soon as possible within 4 days (96 hours); if more than 4 days have passed, skip the missed dose and take the next one on the regularly scheduled day [1]. The day of weekly administration can be changed as long as the time between the two doses is at least 3 days (72 hours) [1]. Zepbound can be injected at any time of day, with or without food, into the abdomen, thigh or back of the upper arm (the upper arm by another person), rotating sites [1].

When nausea needs more than a schedule change

The label lists several situations that are not about titration. Zepbound is not recommended in patients with severe gastroparesis [1]. It warns about acute kidney injury from volume depletion, noting that the majority of reported events occurred in patients who had gastrointestinal reactions leading to dehydration such as nausea, vomiting or diarrhea, and says to monitor renal function in patients reporting reactions that could lead to volume depletion, especially during dose initiation and escalation [1].

For pancreatitis, the label describes persistent or severe abdominal pain, sometimes radiating to the back, which may or may not be accompanied by nausea or vomiting, and says to discontinue Zepbound if pancreatitis is suspected [1].

What about doses below 2.5 mg or partial doses?

The lowest dose in the labeled schedule is 2.5 mg once weekly, which the label describes as an initiation dose and not an approved maintenance dose [1]. The label lists three presentations: a vial, a prefilled single-dose pen and a single-patient-use KwikPen, with dosing described in 2.5 mg increments up to a maximum of 15 mg weekly [1].